July 2019
Volume 60, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2019
Genetic factors associated with the treatment response to reduced-fluence photodynamic therapy for chronic central serous chorioretinopathy
Author Affiliations & Notes
  • Akiko Miki
    ophthalmology, Kobe University Graduate School of Medicine, Kobe, HYOGO, Japan
  • Mayuka Hayashida
    ophthalmology, Kobe University Graduate School of Medicine, Kobe, HYOGO, Japan
  • Shunichiro Nakai
    ophthalmology, Kobe University Graduate School of Medicine, Kobe, HYOGO, Japan
  • Wataru Matsumiya
    ophthalmology, Kobe University Graduate School of Medicine, Kobe, HYOGO, Japan
  • Hisanori Imai
    ophthalmology, Kobe University Graduate School of Medicine, Kobe, HYOGO, Japan
  • Sentaro Kusuhara
    ophthalmology, Kobe University Graduate School of Medicine, Kobe, HYOGO, Japan
  • Shigeru Honda
    ophthalmology, Osaka city university, Japan
  • Makoto Nakamura
    ophthalmology, Kobe University Graduate School of Medicine, Kobe, HYOGO, Japan
  • Footnotes
    Commercial Relationships   Akiko Miki, None; Mayuka Hayashida, None; Shunichiro Nakai, None; Wataru Matsumiya, None; Hisanori Imai, None; Sentaro Kusuhara, kobe university (P); Shigeru Honda, None; Makoto Nakamura, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 5028. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Akiko Miki, Mayuka Hayashida, Shunichiro Nakai, Wataru Matsumiya, Hisanori Imai, Sentaro Kusuhara, Shigeru Honda, Makoto Nakamura; Genetic factors associated with the treatment response to reduced-fluence photodynamic therapy for chronic central serous chorioretinopathy. Invest. Ophthalmol. Vis. Sci. 2019;60(9):5028. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate genetic factors associated with the treatment response to reduced-fluence photodynamic therapy (RFPDT) for chronic central serous chorioretinopathy (cCSC).

Methods : This was a retrospective study of 85 eyes from 85 patients with cCSC who underwent RFPDT and were followed up for more than 12 months. Patients were divided into good response group (54 patients in group A) and poor response group (31 patients in group B) based on either persistence or recurrence of subretinal fluid detected by spectral domain optical coherence tomography after first RFPDT. Genotyping of four single nucleotide polymorphisms (SNPs), including age-related maculopathy susceptibility (ARMS2) A69S (rs10490924), complement factor H (CFH) I62V (rs800292), CFH Y402H (rs1061170) and CFH (rs1329428) was conducted using TaqMan technology.

Results : There were no significant differences in baseline characteristics including sex, age and best corrected logMAR visual acuity between groups. However, there was a significant difference in T-allele frequency in ARMS2 A69S (rs10490924) between groups (24.5% in group A, 40.3% in group B, p=0.032).

Conclusions : ARMS2 variants might be associated with the treatment response of RFPDT in cCSC patients.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×